Rehabs that target lipids called ceramides might hold prospective for dealing with cardiometabolic illness, argues an evaluation short article published today (November 5th, 2021) in the journal Trends in Pharmacological Sciences. The authors summarize proof supporting a strong relationship between ceramides and a series of diseases in animals and human beings and compare it to the years of datasets that drove the production of cholesterol-lowering pharmaceuticals.
” Scientists have a lot to do if we are going to recognize the potential of ceramide-lowering therapies,” states senior research study author Scott Summers of the University of Utah College of Health. “Our hope with the post was to compare the body of literature on ceramides with that of cholesterol in order to explain the important spaces and emerging questions in the ceramide field. Generally, we desire to get as numerous labs as possible studying this essential particle.”
Among the most extensively recommended drug classes is statins, which hinder the synthesis of the lipid cholesterol to prevent coronary artery disease. Statins also minimize blood levels of other lipids such as ceramides. Compared to what we know about cholesterol, much less is understood about the role of ceramides in disease. It is becoming increasingly clear that ceramides are linked to a broad swath of health issues.
Over the past couple of years, research studies in people have shown that ceramides are standalone biomarkers of cardiovascular illness, independent of cholesterol. Ceramides strongly predict significant unfavorable cardiovascular occasions, including death due to coronary artery illness and acute coronary syndrome. These outcomes have been replicated throughout the world in different nations and ethnicities, highlighting the robust nature of the association. Unlike cholesterol, ceramides have actually likewise been connected to metabolic conditions such as insulin resistance and diabetes in human beings. Blood ceramides are now being measured clinically to assess illness risk.
Lowering ceramides through hereditary or medicinal interventions avoids cardiovascular illness and diabetes in rodents. “Ceramides might prove to be as unhealthy as cholesterol, as they generate a non-overlapping spectrum of tissue problems and eventually activate cell death,” Summers says.
More research is likewise needed to understand the hereditary abnormalities that drive high ceramide levels and how ceramides damage cells and tissues. According to the posts authors, addressing these questions might shed light on prospective restorative techniques to safely and efficiently lower ceramides and deal with cardiometabolic disease.
Recommendation: “Cholesterol– the devil you understand; ceramide– the devil you do not” by Tippetts et al., 5 November 2021, Trends in Pharmacological Sciences.DOI: 10.1016/ j.tips.2021.10.001.
This work was supported by the National Institutes of Health, the Juvenile Diabetes Research Foundation, the American Diabetes Association, the American Heart Association, and the Margolis Foundation. Scott Summers is an expert, co-founder, and shareholder of Centaurus Therapeutics.
“Our hope with the article was to compare the body of literature on ceramides with that of cholesterol in order to point out the vital gaps and emerging concerns in the ceramide field. Compared to what we know about cholesterol, much less is known about the role of ceramides in disease. Over the previous couple of years, studies in human beings have actually shown that ceramides are standalone biomarkers of cardiovascular disease, independent of cholesterol. More research study is likewise required to comprehend the genetic problems that drive high ceramide levels and how ceramides damage cells and tissues. According to the short articles authors, answering these concerns might shed light on possible therapeutic methods to securely and effectively lower ceramides and deal with cardiometabolic illness.
